Investor Relations

Company Overview

Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private equity subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury (TBI).

Recent Event

Interdisciplinary Conference on Psychedelic Research

Corporate Fact Sheet

View Corporate Fact Sheet

Latest Financial Results

FY 2022

Fiscal Year Ended Aug 31, 2022

Stock Snapshot

IR Contacts


Algernon Pharmaceuticals Inc.
601 West Broadway
Suite 400
Vancouver, BC V5Z 4C2
T: 604-398-4175

Investor Relations

Christopher J. Moreau
Chief Executive Officer
T: 604-398-4175

Transfer Agent

TSX Trust Company
1066 W. Hastings Street
Suite 1600
Vancouver, BC V6E 3X1
T: 604-235-3700